Our competition and somewhat good news. MEDIF update us pls. IGC pharma is developing like us a drug for Alzheimer agitation disorder
https://youtu.be/op8VMy43rFQ?si=y3SHC5hVLhTjSlBt&t=74
They said this is the first natural cannabis investigational drug being tested on humans for Alzheimer patient, which is totally false. They were at phase 1 in May 2023 when we published this in March 2023 (phase 2).
| Researcher | Indication | Phase | Recent Milestone |
| USC (University of Southern California) Keck School of Medicine | Treatment of Alzheimer's Agitation Disorder | Two | FDA approval of Investigational New Drug (IND) |
| | | | |
https://www.newswire.ca/news-releases/medipharm-labs-provides-update-on-clinical-trial-progress-including-fda-approval-of-partner-study-871567881.html
They recently released preliminary data:
''with interim results based on a group of 26 participants. All told, between the IGC-AD1 and placebo groups, results at 6 weeks showed a between-group difference of –10.45 ''
''the announced results, investigators drew comparisons of IGC-AD1 to brexpiprazole and the phase 3 studies it was approved on. In the 2 phase 3 studies that brexpiprazole was approved on (NCT03548584; NCT1862640), the atypical antipsychotic demonstrated LS treatment differences of –5.32''
The drug seems to be better than the one currently on the market.
https://www.neurologylive.com/view/emergence-igc-ad1-novel-therapy-for-alzheimer-disease-agitation
They use CBD and THC.
If someone can find additional info on our study, it would be much appreciated.